Fosun Pharmaceutical: The registration application of its holding subsidiary, Diclofenac Hydrochloride Gel, has been accepted.

Fosun Pharmaceutical announced that its holding subsidiary, Shanghai Chaohui Pharmaceutical, has had its registration application for Lidocaine Hydrochloride Gel accepted by the National Medical Products Administration. The drug is a chemically developed product by the group, intended for topical anesthesia. By December 2025, the group had invested approximately 7.19 million yuan in research and development for this drug. In 2024, the drug had domestic sales of about 443 million yuan. Before the drug can be commercially produced, it needs to go through multiple approvals, and the acceptance of this application does not currently impact the performance of the group, with sales being uncertain.